Lead Product(s): Live Attenuated Mycobacterium Tuberculosis Vaccine
Therapeutic Area: Infections and Infectious Diseases Product Name: MTBVAC
Highest Development Status: Phase III Product Type: Vaccine
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership July 14, 2021
MTBVAC is a highly promising vaccine candidate that has the potential to be used as an alternative to BCG vaccination in infants and for prevention of TB disease in adolescents and adults.
Lead Product(s): Plitidepsin
Therapeutic Area: Infections and Infectious Diseases Product Name: Aplidin
Highest Development Status: Phase III Product Type: Peptide
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 26, 2021
The APLICOV-PC study evaluated three cohorts of hospitalized patients with mild, moderate or severe disease, with three different dose levels of plitidepsin (1.5mg - 2.0mg - 2.5mg), administered on three consecutive days.